Autonomic Drug Challenges Helped Interpret Repeated THC Responses in Rhesus Monkeys

A 1981 rhesus-monkey study used autonomic drug challenges and reflex measurements to investigate repeated THC responses. Its proposed shift in autonomic control was an interpretation supported by those interventions, rather than a direct measure of a human clinical condition.

Acute responses had several components

The first administration produced increased heart rate and lower blood pressure, sometimes preceded by a transient pressure increase. During repeated dosing, tolerance developed to the heart-rate increase and transient systolic increase, while the pressure-lowering response persisted.

Between-dose observations added information

Measurements between injections showed heart-rate decreases that became tolerant and blood-pressure decreases that remained sustained. A brief post-dose observation would therefore not describe the entire repeated-exposure profile. Timing within the dosing cycle was part of the result.

Autonomic probes supported an interpretation

Changes after beta-adrenergic and cholinergic blockade, together with increased reflex slowing in response to a pressure challenge, led the authors to suggest a shift toward parasympathetic dominance. The probe responses support a mechanistic interpretation of this primate protocol, not a demonstrated autonomic diagnosis in a cannabis user.

Interpreting the evidence

The study supports endpoint- and time-specific cardiovascular interpretation. It does not establish a human response to ordinary cannabis products or show that heart-rate tolerance protects against blood-pressure effects. Species, intravenous exposure and the repeated-dose regimen limit its translation.

Related reading: interpreting cannabis tolerance claims.

Research reference

Fredericks AB; Benowitz NL; Savanapridi CY (1981). The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us